Preparation and preclinical evaluation of (177)Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors

0374499 - ÚJF 2012 RIV GB eng J - Článek v odborném periodiku
Beckford, Denis R. - Eigner, Sebastian - Eigner-Henke, Kateřina - Lebeda, Ondřej - Melichar, František - Beran, Miloš
Preparation and preclinical evaluation of (177)Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
Nuclear Medicine and Biology. Roč. 39, č. 1 (2012), s. 3-13. ISSN 0969-8051. E-ISSN 1872-9614
Grant CEP: GA MŠMT 2B06165
Výzkumný záměr: CEZ:AV0Z10480505
Klíčová slova: Radioimmunotherapy * Nimotuzumab * (177)Lu * Monoclonal antibody
Kód oboru RIV: FR - Farmakologie a lékárnická chemie
Impakt faktor: 2.517, rok: 2012

Objectives: Nimotuzumab (h-R3) is a humanized monoclonal antibody (mAb) which recognizes the external domain of the epidermal growth factor receptor (EGFR) with high specificity. It was demonstrated that h-R3 has a unique clinical profile for immunotherapy of adult gliomas and pediatric pontine gliomas. The aim of this work was to evaluate the conjugate (177)Lu-h-R3 as a potential radioimmunoconjugate for radioimmunotherapy (RIT) of tumors overexpressing EGER.
Trvalý link: http://hdl.handle.net/11104/0207407